UnknownNot Applicable

A Prospective Study to Investigate Contact Sensitization Using Classic and Machine Learning Techniques

Greece80 participantsStarted 2023-06-30

Plain-language summary

The goal of this study is to look into the patterns of sensitization to figure out how allergic contact dermatitis (ACD), individual susceptibility, and patient characteristics are connected. The joint application of classic statistics and machine learning methods will reveal the relationship between contact dermatitis expressions and several clinical characteristics.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Eligible patients were adults diagnosed with dermatitis who had a positive patch test result on the chemical panel of Baseline Series of Allergens. Exclusion Criteria: \- Although there is no consensus for the definitive exclusion criteria from a patch testing, most studies agree that the chronic use of anti-inflammatory treatments, corticosteroids, and cyclosporine, high UV exposure and other chronic dermatoses are factors that might produce false- positive or false- negative results and thus should be avoided.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

MOAHLFAP index

Timeframe: Clinical examination at baseline (0h)

International Contact Dermatitis Research Group (ICDRG) scale

Timeframe: 48 hours (Day 2) and 72 hours (Day 3) after the application of patch test

Antera 3D camera (Miravex, Dublin, Ireland)

Timeframe: 0h (baseline), 48 hours (Day 2) and 72 hours (Day 3) after the application of patch test

Trial details

NCT IDNCT05991674

SponsorAndreas Syggros Hospital of Venereal and Dermatological Diseases

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-10-30

Contact for this trial

Aikaterini Kyritsi

+30 2107274027 akyrits@pharm.uoa.gr

View on ClinicalTrials.gov More Allergic Contact Dermatitis trials